Impact of Concomitant Cardiovascular Medication on Survival of Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib or Pazopanib in the First Line
Ondřej Fiala, Pavel Ostašov, Aneta Rozsypalová, Milan Hora, Ondřej Šorejs, Jan Šustr, Barbora Bendová, Ivan Trávníček, Jan Filipovský, Jindřich Fínek, Tomáš Büchler
Topics & Concepts
MedicineSunitinibPazopanibRenal cell carcinomaInternal medicineHazard ratioProportional hazards modelOncologyConcomitantConfidence intervalCancer, Stress, Anesthesia, and Immune ResponseCancer, Lipids, and MetabolismRenal cell carcinoma treatment